Alpha-particle therapy shows preclinical promise against bladder cancer cells
A preclinical study reports that 213Bi-labeled trastuzumab plus cetuximab killed human bladder cancer cells in vitro through irreparable DNA damage.
A preclinical study reports that 213Bi-labeled trastuzumab plus cetuximab killed human bladder cancer cells in vitro through irreparable DNA damage.
A retrospective study of 272 breast cancer patients found that a clinical signature based on HER2 and nodal status was ...
A machine-learning analysis of 6,620 ADC patent families identifies 47 technological topics and ten central knowledge hubs spanning targets, payloads, ...
The work, led by Roney Miah and colleagues, is entirely predictive: no compounds were extracted from the plant and no ...
A systematic review of 25 studies finds optical fiber biosensors can detect cancer biomarkers down to attomolar levels, but most ...
A retrospective study of 74 resected esophagogastric junction adenocarcinomas found longer overall survival in HER2-low tumors, but HER2-low status was ...
An analysis of 219 epithelial ovarian cancers found that HER2 protein expression and gene amplification varied by tumor subtype, while ...
A survey of 27 medical oncologists in Benghazi found that most rate biomarker testing as extremely important for breast cancer ...
A focused review finds that antibody–drug conjugates directly kill breast-cancer cells, while evidence that they remodel human tumor immunity remains ...
UCLA scholars Susan Ettner, Donald Kohn and Dennis Slamon were elected to the National Academy of Medicine for work on ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine